Pacira BioSciences' Other Non-Current Liabilities rose 3208.75% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year increase of 3208.75%. This contributed to the annual value of $20.2 million for FY2024, which is 1804.6% down from last year.
Per Pacira BioSciences' latest filing, its Other Non-Current Liabilities stood at $25.3 million for Q3 2025, which was up 3208.75% from $25.2 million recorded in Q2 2025.
Over the past 5 years, Pacira BioSciences' Other Non-Current Liabilities peaked at $57.6 million during Q4 2021, and registered a low of $11.1 million during Q3 2021.
Moreover, its 5-year median value for Other Non-Current Liabilities was $24.3 million (2023), whereas its average is $27.1 million.
Data for Pacira BioSciences' Other Non-Current Liabilities shows a peak YoY increase of 35752.33% (in 2022) and a maximum YoY decrease of 5117.54% (in 2022) over the last 5 years.
Quarter analysis of 5 years shows Pacira BioSciences' Other Non-Current Liabilities stood at $57.6 million in 2021, then plummeted by 51.18% to $28.1 million in 2022, then dropped by 12.18% to $24.7 million in 2023, then decreased by 18.05% to $20.2 million in 2024, then grew by 25.01% to $25.3 million in 2025.
Its Other Non-Current Liabilities was $25.3 million in Q3 2025, compared to $25.2 million in Q2 2025 and $23.9 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value